Verastem Licenses KRAS G12D Inhibitor VS-7375 Early, Reports Phase 1 Data from GenFleet Study

Verastem, Inc. +5.92% Post

Verastem, Inc.

VSTM

6.08

5.89

+5.92%

-3.13% Post

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it has exercised early the option to license from GenFleet Therapeutics VS-7375 (also known as GFH375), a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor. In addition, the Company announced preliminary clinical data from the Phase 1 study being conducted by GenFleet in China.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via